SkinBioTherapeutics is a life science company focused on skin health. The Company’s proprietary platform technology, SkinBiotix®, is based upon discoveries made by CSO Dr. Catherine O’Neill and Professor Andrew McBain.
SkinBioTherapeutics’ platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to the skin. The Company has shown that the SkinBiotix® platform can improve the barrier effect of skin models, protect skin models from infection and repair models of skin. Proof of principle studies have shown that the SkinBiotix® platform has beneficial attributes applicable to each of these areas. The most advanced programme is focused on creating an ingredient for the cosmetics industry to treat sensitive skin. The business strategy is to outlicense its programmes following completion of human studies/clinical trials.
SkinBioTherapeutics is looking to target three specific areas: cosmetics, infection control and eczema. These areas represent a combined annual global market of over $100 billion and the Company’s initial focus is a cosmetic application for sensitive skin.
SkinBioTherapeutics will seek to enter these markets by partnering with established, global players, which it believes will give the Company access to a greater share of the market than if it acted alone. It also serves to derisk the Company, as marketing and scaling up costs associated with these markets are negated.